More specifically, all patients who completed the double-blind induction phase were administered cendakimab 360 mg weekly, achieving a positive trend in symptom remission (symptom-based EoE activity index score ≤ 20) in all three previous groups [ 42 ].
← all excerpts
The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological Drugs.
1
—
—